These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 20842459

  • 41. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression.
    Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mäder U, Gasser M, Waaga-Gasser AM, Eilers M, Germer CT.
    PLoS One; 2013; 8(10):e75292. PubMed ID: 24098375
    [Abstract] [Full Text] [Related]

  • 42. [Expression and clinical significance of CIP2A in small cell lung cancer patients].
    Deng Y, Xie K, Hu H, Yang L, Bai Y.
    Zhonghua Zhong Liu Za Zhi; 2015 Jul; 37(7):517-20. PubMed ID: 26463328
    [Abstract] [Full Text] [Related]

  • 43. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC).
    Dworakowska D, Jassem E, Jassem J, Peters B, Dziadziuszko R, Zylicz M, Jakóbkiewicz-Banecka J, Kobierska-Gulida G, Szymanowska A, Skokowski J, Roessner A, Schneider-Stock R.
    Lung Cancer; 2004 Mar; 43(3):285-95. PubMed ID: 15165086
    [Abstract] [Full Text] [Related]

  • 44. Differential expression of inflammasomes in lung cancer cell lines and tissues.
    Kong H, Wang Y, Zeng X, Wang Z, Wang H, Xie W.
    Tumour Biol; 2015 Sep; 36(10):7501-13. PubMed ID: 25910707
    [Abstract] [Full Text] [Related]

  • 45. Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas.
    Zhan P, Shen XK, Qian Q, Zhu JP, Zhang Y, Xie HY, Xu CH, Hao KK, Hu W, Xia N, Lu GJ, Yu LK.
    Med Oncol; 2012 Jun; 29(2):648-55. PubMed ID: 21519871
    [Abstract] [Full Text] [Related]

  • 46. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
    Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, Lin SC, Chang YC, Lin SY, Chen SJ, Chen HC, Yeh SD, Wu CW.
    Cancer Res; 2010 Nov 01; 70(21):8822-31. PubMed ID: 20978205
    [Abstract] [Full Text] [Related]

  • 47. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
    Niemelä M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernilä P, Kallioniemi OP, Joensuu H, Hautaniemi S, Westermarck J.
    Oncogene; 2012 Sep 27; 31(39):4266-78. PubMed ID: 22249265
    [Abstract] [Full Text] [Related]

  • 48. Decreased expression of ING2 gene and its clinicopathological significance in Chinese NSCLC patients.
    Pan YQ, Zhang X, Xu DP, Bao WG, Lin AF, Xu HH, Yan WH.
    Neoplasma; 2014 Sep 27; 61(4):468-75. PubMed ID: 24712846
    [Abstract] [Full Text] [Related]

  • 49. High TBX2 expression predicts poor prognosis in non-small cell lung cancer.
    Zhang Z, Guo Y.
    Neoplasma; 2014 Sep 27; 61(4):476-80. PubMed ID: 25027744
    [Abstract] [Full Text] [Related]

  • 50. CIP2A is overexpressed in esophageal squamous cell carcinoma.
    Qu W, Li W, Wei L, Xing L, Wang X, Yu J.
    Med Oncol; 2012 Mar 27; 29(1):113-8. PubMed ID: 21140243
    [Abstract] [Full Text] [Related]

  • 51. Cip2a induces arginine biosynthesis and promotes tumor progression in non-small cell lung cancer.
    Chen D, Fan S, Wang J, Liang Y, Li P, Lv X, Sun Y, Wang Q, Liu H, Zhang C, Yi Y.
    Mol Carcinog; 2023 Apr 27; 62(4):561-572. PubMed ID: 36705466
    [Abstract] [Full Text] [Related]

  • 52. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis.
    Berta J, Kenessey I, Dobos J, Tovari J, Klepetko W, Jan Ankersmit H, Hegedus B, Renyi-Vamos F, Varga J, Lorincz Z, Paku S, Ostoros G, Rozsas A, Timar J, Dome B.
    J Thorac Oncol; 2010 Aug 27; 5(8):1120-9. PubMed ID: 20581707
    [Abstract] [Full Text] [Related]

  • 53. Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor--an expression in non-small-cell lung cancer.
    Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H, Ueno M.
    J Clin Oncol; 2005 Dec 01; 23(34):8765-73. PubMed ID: 16314637
    [Abstract] [Full Text] [Related]

  • 54. Cell cycle protein cyclin Y is associated with human non-small-cell lung cancer proliferation and tumorigenesis.
    Yue W, Zhao X, Zhang L, Xu S, Liu Z, Ma L, Jia W, Qian Z, Zhang C, Wang Y, Yang X.
    Clin Lung Cancer; 2011 Jan 01; 12(1):43-50. PubMed ID: 21273179
    [Abstract] [Full Text] [Related]

  • 55. CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.
    Zhai M, Cong L, Han Y, Tu G.
    Tumour Biol; 2014 Feb 01; 35(2):1123-8. PubMed ID: 24014087
    [Abstract] [Full Text] [Related]

  • 56. Celastrol inhibits chondrosarcoma proliferation, migration and invasion through suppression CIP2A/c-MYC signaling pathway.
    Wu J, Ding M, Mao N, Wu Y, Wang C, Yuan J, Miao X, Li J, Shi Z.
    J Pharmacol Sci; 2017 May 01; 134(1):22-28. PubMed ID: 28522217
    [Abstract] [Full Text] [Related]

  • 57. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
    Wang WP, Yan XL, Li WM, Ni YF, Zhao JB, Lu Q, Wang XJ, Sun Y, Chen P, Yan BY, Cui Y, Zhang ZP, Li XF.
    Pathol Res Pract; 2015 Dec 01; 211(12):939-47. PubMed ID: 26554593
    [Abstract] [Full Text] [Related]

  • 58. CIP2A expression and localization in oral carcinoma and dysplasia.
    Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S, Chan EK.
    Cancer Biol Ther; 2010 Oct 01; 10(7):694-9. PubMed ID: 21068540
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Liu H, Gu Y, Wang H, Yin J, Zheng G, Zhang Z, Lu M, Wang C, He Z.
    Oncotarget; 2015 Jun 20; 6(17):14913-25. PubMed ID: 25945834
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.